Serkan Yaras, Mehmet Demir, Sezgin Barutcu, Abdullah Emre Yildirim, Selim Gurel, Enver Ucbilek, Ilkce Akgun Kurtulmus, Meral Akdogan Kayhan, Sezgin Vatansever, Haydar Adanir, Nilay Danis, Serkan Duman, Ilker Turan, Derya Ari, Sukran Kose, Huseyin Alkim, Muhsin Murat Harputluoglu, Feyza Dilber, Murat Akyildiz, Arif Mansur Cosar, Serdar Durak, Goktug Sirin, Ayse Kefeli, Hale Gokcan, Ufuk Avcioglu, Talat Ayyildiz, Orhan Sezgin, Mesut Akarsu, Dinc Dincer, Fatih Guzelbulut, Fulya Gunsar, Ulus Salih Akarca, Ramazan Idilman
{"title":"格列卡韦/皮布伦他韦治疗实际慢性丙型肝炎患者队列的疗效和耐受性。","authors":"Serkan Yaras, Mehmet Demir, Sezgin Barutcu, Abdullah Emre Yildirim, Selim Gurel, Enver Ucbilek, Ilkce Akgun Kurtulmus, Meral Akdogan Kayhan, Sezgin Vatansever, Haydar Adanir, Nilay Danis, Serkan Duman, Ilker Turan, Derya Ari, Sukran Kose, Huseyin Alkim, Muhsin Murat Harputluoglu, Feyza Dilber, Murat Akyildiz, Arif Mansur Cosar, Serdar Durak, Goktug Sirin, Ayse Kefeli, Hale Gokcan, Ufuk Avcioglu, Talat Ayyildiz, Orhan Sezgin, Mesut Akarsu, Dinc Dincer, Fatih Guzelbulut, Fulya Gunsar, Ulus Salih Akarca, Ramazan Idilman","doi":"10.14744/hf.2023.2023.0001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aim: </strong>The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).</p><p><strong>Materials and methods: </strong>Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.</p><p><strong>Results: </strong>All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.</p><p><strong>Conclusion: </strong>GLE/PIB is an effective and tolerable treatment in patients with CHC.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/90/hf-4-092.PMC10564251.pdf","citationCount":"0","resultStr":"{\"title\":\"The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.\",\"authors\":\"Serkan Yaras, Mehmet Demir, Sezgin Barutcu, Abdullah Emre Yildirim, Selim Gurel, Enver Ucbilek, Ilkce Akgun Kurtulmus, Meral Akdogan Kayhan, Sezgin Vatansever, Haydar Adanir, Nilay Danis, Serkan Duman, Ilker Turan, Derya Ari, Sukran Kose, Huseyin Alkim, Muhsin Murat Harputluoglu, Feyza Dilber, Murat Akyildiz, Arif Mansur Cosar, Serdar Durak, Goktug Sirin, Ayse Kefeli, Hale Gokcan, Ufuk Avcioglu, Talat Ayyildiz, Orhan Sezgin, Mesut Akarsu, Dinc Dincer, Fatih Guzelbulut, Fulya Gunsar, Ulus Salih Akarca, Ramazan Idilman\",\"doi\":\"10.14744/hf.2023.2023.0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aim: </strong>The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).</p><p><strong>Materials and methods: </strong>Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.</p><p><strong>Results: </strong>All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.</p><p><strong>Conclusion: </strong>GLE/PIB is an effective and tolerable treatment in patients with CHC.</p>\",\"PeriodicalId\":29722,\"journal\":{\"name\":\"Hepatology Forum\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/90/hf-4-092.PMC10564251.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Forum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/hf.2023.2023.0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Forum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/hf.2023.2023.0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort.
Background and aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC).
Materials and methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study.
Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed.
Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
